Philip J. Larsen
Rheoscience
Copenhagen
Denmark
Name/email consistency: high
- Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats. Larsen, P.J., Wulff, E.M., Gotfredsen, C.F., Brand, C.L., Sturis, J., Vrang, N., Knudsen, L.B., Lykkegaard, K. Diabetes. Obes. Metab (2008)
- Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Larsen, P.J., Holst, J.J. Regul. Pept. (2005)
- Cocaine- and amphetamine-regulated transcript is present in hypothalamic neuroendocrine neurones and is released to the hypothalamic-pituitary portal circuit. Larsen, P.J., Seier, V., Fink-Jensen, A., Holst, J.J., Warberg, J., Vrang, N. J. Neuroendocrinol. (2003)
- Central pre-proglucagon derived peptides: opportunities for treatment of obesity. Larsen, P.J., Vrang, N., Tang-Christensen, M. Curr. Pharm. Des. (2003)
- Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis. Larsen, P.J., Jensen, P.B., Sørensen, R.V., Larsen, L.K., Vrang, N., Wulff, E.M., Wassermann, K. Diabetes (2003)









